The CD9 antigen, a major platelet glycoprotein, is a member of expressed by megakaryocytes and platelets, on which it is a the tetraspan superfamily. We show that treatment of K562 major surface protein with 35 000-60 000 molecules per cell, 
K562 is a pluripotent hematopoietic cell line initially derived from a patient with a Philadelphia chromosome-positive chronic myelogenous leukemia. 34 HEL is derived from an Introduction erythroleukemia. 35 Nalm6 and Reh6 cell lines, respectively CD9 positive and CD9 negative or weakly positive, are The CD9 antigen is a 24 kDa glycoprotein member of the derived from B lineage acute lymphoblastic leukemias. CEM, tetraspan superfamily. 1, 2 These proteins are characterized by Raji and Daudi are CD9-negative cell lines, respectively four transmembrane domains with intracytoplasmic extremiderived from a human T cell leukemia and from Burkitt lymties and sequence homologies that distinguish them from the phomas. The cells were cultured in RPMI 1640 medium supother proteins with four transmembrane domains. Several difplemented with 10% FCS, 2 mM L-glutamine and antibiotics ferentiation and tumoral antigens are members of the tetras-(all from Gibco, Gaithersburg, MD, USA). 12-O-tetrapan family, including CD37, CD53, CD63, CD81/TAPA-1, decanoylphorbol-13-acetate (TPA) and hemin were added to CD82, CD151/PETA-3, L6, Co029 and TALLA-1. [3] [4] [5] The differgive a final concentration of 16 nM (10 ng/ml) and 100 M, ent tetraspans may derive from the duplication of an ancestral respectively. Erythroid differentiation was evaluated by detecgene because they are encoded by genes with similar genomic tion of benzidine-stainable hemoglobin after addition of structure. [6] [7] [8] [9] [10] [11] Furthermore, two proteins of the tetraspan fam-100 l of benzidine solution to 100 l of cells suspended in ily were found in the parasite worm Schistosoma 12, 13 and one culture medium. 36 Cells were incubated on ice for 5 min and is expressed by motoneurons in Drosophila 14 which strongly examined for benzidine positivity (blue staining). Cyclohexisuggests an early appearance in evolution.
mide (2 and 10 g/ml) and actinomycin D (1 g/ml) (both The exact function of these molecules is still unknown.
from Boehringer, Meylan, France), were added 30 min before Recent studies have suggested that CD9 antigen may be TPA treatment. The PKC inhibitor GF109203X (Calbiochem, involved in migration and adhesion processes [15] [16] [17] [18] functions Meudon, France) was added 45 min before TPA treatment at that may be related to its association with VLA integrins. 17, 19, 20 the concentration of 5 M. The CD9 antigen is also associated with the transmembrane precursor of heparin-binding EGF (HB-EGF) and upregulates the juxtacrine activity of this receptor as well as its activity as Monoclonal antibodies and flow cytometry analysis the receptor for diphtheria toxin. 21, 22 Certain members of this family have been reported to trigger an activation signal
The CD9 mAb SYB-1 has been previously described. 17, 32 Anti-(CD81, CD82 and CD53). [23] [24] [25] [26] body Gi9 (VLA-2) was purchased from Immunotech (Luminy, The CD9 antigen is expressed in various tissues. In the France). The anti-VLA␤1 mAb C9 was provided by Dr Zardi hematopoietic tissue it is found at the surface of basophils, (Genoa, Italy). The GPIIb mAb D33C and the GPIIIa mAb B2A eosinophils, PHA-activated T lymphocytes and early B were obtained from Dr Gulino. 37 The glycophorin A mAb cells.
27,28 It is not found on erythrocytes but is strongly MAS 517P was purchased from Valbiotech (Paris, France) and the anti-integrin ␣v mAb LM609 was purchased from Chemicon (Temecula, CA, USA). Cell transfection and CAT assays reverse transcription buffer (10 mM Tris-HCl (pH 9.0 at 25°C), 50 mM KCl, 0.1% Triton X-100, 7 mM MgCl 2 , 2 mM dithiotreiDifferent fragments of the 5′-flanking region of CD9 gene were tol, 0.25 mM of each deoxynucleotide triphosphate (dNTP), cloned ahead of the chloramphenicol acetyl transferase (CAT) 0.25 U/l RNAsin (Promega, Charbonnières, France), gene in the promoterless pCATbasic vector (Promega) as 0.625 ng/l of random hexamer primers (Promega) and described in a previous report. 40 Because the CD9 gene has 0.2 U/l of avian myeloblastosis virus reverse transcriptase several transcription initiation sites, 11 all positions are given (Promega). The reaction mixture was incubated at room temrelative to the translation initiation site. K562, HEL and Daudi perature for 10 min and 42°C for 1-2 h and then heated to cells, were transfected by the electroporation method using a 95°C for 5 min. The PCR was then performed uisng 2 l of gene pulser apparatus (Biorad, Hercules, CA, USA). Typically, cDNA added to 100 l of amplification mixture (50 mM KCl, 10 7 cells in 0.7 ml PBS, 50 mM Hepes, pH 7.4 were electropo-10 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , gelatin 0.01%) conrated at 4°C with 20 g of each plasmid. The conditions were taining 0.25 M of 5′-biotin labeled and 3′ primers with 420 V and 960 F for HEL cells, 400 V and 500 F for K562 2.5 U/reaction Taq polymerase (Beckman, Gagny, France).
and Daudi cells. The efficiency of transfection was controlled Temperature was initially at 94°C for 3 min, followed by as previously described. 40 TPA was added 2 h after transfeccycles at 94°C for 1 min, 65°C for 1 min, and 72°C for 1 tion. The determination of CAT activity was performed 2 days min in a thermal cycler (PCH-3, Techne apparatus (Techne, after electroporation as described by Gorman et al. 41 Cells Cambridge, UK)). Aliquots of 10 l were removed every three were washed twice in PBS and lysed in 250 mM Tris-HCl pH 8 cycles for quantification, starting at cycle 18. The PCR product by three cycles of freeze-thaw. After centrifugation, the insolwas then captured on avidin-coated plates. The second strand uble material was discarded, the extracts were heated at 65°C was denatured by treatment with NaOH (0.1 M), and the capto eliminate endogenous acetylases and the protein concentured strand was probed with an oligonucleotide 3′ end labtration in the supernatants was determined by the Bradford eled with digoxigenin (Boehringer, Mannheim, Germany).
assay. CAT activity was assayed in 250 mM Tris-HCl pH 8 After washing, the bound probe was detected by an alkaline (200 l reaction) with 20 g of protein extract, 0.2 Ci 14 Cphosphatase-labeled anti-digoxigenin mAb (Boehringer) and chloramphenicol (NEN) and 2 mM acetylcoenzyme A. After revealed by either a colorimetric method (GAPDH and CD9) incubation at 37°C (3 h for K562 cells and 16 h for HEL and or by luminometry. Quantification of RNA was performed as Daudi cells), the chloramphenicol and acetylated products follows: experimental curves (OD or light units vs number of were extracted by ethyl acetate and separated by thin-layer cycles) were matched to a standard curve generated by amplichromatography in chloroform/5% methanol. Quantification fying a serially diluted cDNA in the same experiment. For was performed with a phosphorimager using the ImageQuant greater accuracy, the comparisons were made by using the software (Molecular Dynamics, Evry, France). For each confollowing strategy. The number of cycles necessary to obtain struct, several experiments with independent preparations of an OD (or light unit) closed to the half maximum point was DNA were performed. determined from the experimental curves for each diluted standard. This new value was then plotted against the corresponding input DNA concentrations (log scale) to generate a Immunoprecipitation and Western blotting line which was fit by the linear least-squares function in Microsoft Excel. The amount of cDNA in each sample was then determined using this equation and the number of cycles 3 × 10 6 cells were washed three times in HBSS and lysed in 1.5 ml of lysis buffer (1% CHAPS, 10 mM Tris pH 7.4, 150 mM necessary to obtain the value previously chosen. To check for variability in RNA recovery and efficiency of reverse transcripNaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.02% NaN 3 , 1 mM PMSF, 0.5 g/ml leupeptin, 1 g/ml pepstatin A and 10 KIU/ml tion, GAPDH cDNA was also amplified from each cDNA preparation. aprotinin). After 30 min incubation at 4°C, the insoluble material was removed by centrifugation at 10 000 r.p.m., and For the colorimetric method, the substrate was p-NPP substrate (Sigma, St Louis, MO, USA) and the OD was measured the lysate was precleared overnight by incubation with protein G-sepharose beads. Proteins were then immunoprecipated by at 405 nm. Luminescence was measured by using the EG&G Berthold luminometer (Bad-Wildbad, Germany), after incuadding to the supernatant 25 g/ml mAb (or 1:200 ascite fluid) and 1/10th volume protein G-sepharose beads (Pharmacia, bation of samples with disodium 3-(4-methoxyspirol[1,2 Saclay, France). After 5 h incubation at 4°C under constant CD9 was increased seven-fold after 24 h TPA treatment ( Figure 1 ). This effect was observed with concentrations of agitation, the beads were washed five times in lysis buffer and the proteins separated by SDS-PAGE in non-reducing con-TPA ranging from 0.16 to 16 mM (10 ng/ml), but not with 0.016 nM TPA (data not shown). K562 cells were also treated ditions. The proteins were then transferred to a PDVF membrane (NEN) in a buffer containing 25 mM Tris, 192 mM glywith hemin (100 M) in order to induce erythroid differentiation. After 3 days, 70% of the cells were benzidine positive cine and 20% methanol, and the membrane was blocked overnight in 5% non-fat dry milk in TBS containing 0.05% and expressed glycophorin A. In these conditions, the expression of CD9 remained similar (data not shown). In order Tween. The membrane was then incubated 1 h in TBS-tween containing the biotinylated antibody, and after several washto determine the specificity of the TPA effect on CD9 expression, and its possible relationship with megakaryocytic ings, in TBS-tween containing streptavidin-biotinylated horseradish peroxidase complex (Amersham, Les Ulis, France).
differentiation, other cell lines were tested. No significant changes in CD9 expression were observed when the lymphThe proteins were then revealed by chemiluminescence (NEN, Les Ulis, France).
oid cell lines Nalm-6 (CD9 + ), CEM, Daudi and Raji (CD9 − ) were treated with TPA indicating that the upregulation or the induction of CD9 by TPA is not a general phenomenon (data not shown). On the other hand, in the pre-B cell line Reh6 Results and discussion which does not or weakly expresses CD9, TPA treatment induced a high expression of this molecule, confirming a preIncreased expression of CD9 antigen in TPA-treated K562 cells vious report 48 (data not shown). Another erythroleukemia cell line with megakaryocytic features, HEL, was also treated with TPA. CD9 expression was poorly modified (less than 1.5-fold Undifferentiated K562 cells express surface markers or properties characteristic of erythroid (expression of glycophorin A), increase, data not shown), which is not surprising considering the high level of CD9 in this cell line (comparable to the level myeloid (expression of CD15) or megakaryocytic lineages (peroxidase activity). 42, 43 In the presence of phorbol esters, of TPA-treated K562 cells, data not shown). Because HEL, but not K562, spontaneously expresses megakaryocytic markers K562 cells differentiate along the megakaryocytic lineage with an accompanying increase in expression of megakaryocytic such as GPIIb or GPIIIa (Ref. 49 and data not shown), the higher expression of CD9, and the absence of effect of TPA markers such as GPIIb, GPIIIa and VLA-2, and concomitant decrease in expression of markers of the other two linin HEL cells may be related to a more advanced commitment in the megakaryocytic lineage. eages. 42, [44] [45] [46] [47] Because CD9 is expressed by megakaryocytes but not erythrocytes, we have examined the effect of TPA on the expression of this antigen. Upon addition of TPA, the rounded nonadherent morphology of K562 cells changed to Increased CD9 expression precedes the appearance of megakaryocytic markers an adherent, highly elongated, and partially spread phenotype as previously described. 44 In these conditions, the level of CD29 (VLA␤1 integrin) was not modified (Figure 1 ), conWe next compared the kinetic of upregulation of CD9 with that of the other megakaryocytic markers. The only tissuefirming previous reports. 46, 47 By contrast, the expression of specific molecule, GPIIb, could be detected by flow cytometry after 48 h of treatment ( Figure 2 ). VLA-2 and GPIIIa expressions increased from 10 to 72 h of treatment (Figure 2 ). At any time during the induction, the expression of GPIIIIa was higher than the expression of GPIIb. Because integrins are heterodimers, 50 GPIIIa is likely to associate with another partner, probably the integrin ␣v (CD51) which is induced at the same time (Figure 2 ). Contrasting with these markers, the enhancement of CD9 expression was detectable on most cells after 5 h of treatment with TPA, reached maximum after 16-20 h and remained stable for several days. Interestingly, in Reh6 cells, the expression of CD9 antigen was only observed after 10 h of treatment (data not shown).
CD9 upregulation is blocked by the protein kinase C-specific inhibitor GF109203X
TPA is known to activate the molecules of the PKC family, but also several other molecules such as the guanine nucleotide exchange factor vav and members of the chimaerin family. 51, 52 ␣PKC has been shown to be specifically induced during the PMA treatment of K562 cells, suggesting a role for this isotype in the megakaryocytic differentiation of these cells. 53 Recently, it was also reported that GF109203X, the most 
PMA
. 55 We now demonstrate that GF109203X prevents the C9 (CD29, lower panel) and analyzed by flow cytometry. Dotted line is the control staining.
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Accumulation of CD9 mRNA precedes the increase of GPIIb mRNA
The levels of CD9 mRNA in K562 cells were then measured by quantitative RT-PCR. An increase of the steady-state levels of CD9 mRNA could be observed as early as 1 h after TPA treatment. This increase was Ϸ15-fold over the control level after 4 to 6 h of treatment (Figure 4) . The protein synthesis inhibitor cycloheximide and the transcription inhibitor actinomycin D prevented the accumulation of CD9 mRNA (data not shown). Low levels of GPIIb RNA could be detected in unstimulated K562 cells, confirming a previous report. 46 It is possible that the absence of GPIIb at cell surface results from the lack of GPIIIa transcription. Indeed, it has been shown that assembly of GPIIb with GPIIIa is a prerequisite for expression of the complex. 56 Contrasting with CD9, no increase of GPIIb mRNA was observed before 24 h of treatment ( Figure 5 ). The increase of CD9 mRNA levels is almost as fast as described for immediate-early genes such as Egr1 (encoding for a zinc finger transcription factor). Egr1 mRNA is induced in K562 cells 30 min after phorbol ester treatment. 57 These effects are concomitant with the down-modulation of GATA-1, which occurs within 4 h, during the TPA-induced differentiation of K562 cells. promoter of the CD9 gene
We have previously described the 5′-flanking region of the K562 cells. Moreover, this compound also blocks the upregul-CD9 gene, and reported that this region supports a promoter ation of CD9 (Figure 3 ). This shows that in K562 cells, both activity in HEL cells when cloned ahead of a CAT reporter CD9 upregulation and GPIIb/IIIa expression are induced by a gene. 40 This construct had a poor activity when transfected in PKC-dependent pathway.
K562 cells. We tested the effect of TPA on the promoting activity of several constructs of the CD9 promoter cloned ahead of the CAT reporter gene ( Figure 6 ). TPA induced a strong increase (up to 24 times) in the production of CAT when The mechanism which mediates phorbol ester responsiveness in this model is not completely determined, since the CD9 promoter, like the GPIIb promoter, 58 does not contain a perfect AP-1 consensus sequence. However, an AP2 site (5′-(C/T)C(G/C)CC(A/C)N(G/C) (G/C)(G/C)-3′) 59 was found in the 5′ extremity of the −205, −154 region. 11 Interestingly, the 52 bp region has previously been shown to be responsible for most of the promoting activity of the 5′-flanking region of the CD9 gene in HEL cells. 40 Moreover, this region supports the cell specificity since TPA did not induce any increase of activity above control when the constructions were transfected in Daudi or in HEL cell lines, which are not responsive to TPA in terms of efficiently transfected. 
CD9 associates with VLA␤1 upon TPA stimulation
The function of CD9 and other tetraspans is not clearly understood. It may, however, be linked to associated surface molecules. Indeed, CD9 is associated with VLA integrins in a variety of cell lines, including the megakaryocytic-like cell line HEL. 17, 19, 20 The presence of VLA␤1 in CD9 immunoprecipitates was investigated by Western blot (Figure 8 ). In this technique, the VLA␤1 mAb recognizes two bands corresponding to the mature (Ϸ135 kDa) and immature (Ϸ125 kDa) forms of the protein (Ref. 60 and Rubinstein et al, submitted for publication). We could not detect any coprecipitation of VLA␤1 with CD9 in K562 cells. However, after TPA treatment, the VLA␤1 molecule could be clearly detected in the CD9 immunoprecipitate, suggesting that the induction of CD9 by TPA is functionally relevant.
Concluding remarks
The CD9 antigen has long been described as a target for mAbs that activate platelets. However, these mAbs activate platelets by recruitment and oligomerization of the Fc receptor, as do activating mAbs directed against other platelet antigens. 33 When interaction with the Fc receptor is impaired, by using F(ab′) 2 fragments or blocking this receptor by specific mAbs, there is no evidence of activation or signal transduction (including calcium mobilization and tyrosine protein phosphorylation), suggesting that the CD9 antigen is not a transduction molecule in platelets. Recent studies have suggested that CD9 may be involved in the migration and the aggregation of different cell lines, [15] [16] [17] including the HEL cell line. Because both aggregation and inhibition of migration are also triggered by CD29 (VLA␤1) mAbs, and CD9 antigen is 
Figure 8
Association of CD9 and integrin ␤1 in TPA-treated K562 cells. Extracts of K562 cells treated or not with TPA for 24 h were Figure 7 Specificity of the TPA-responsive element of the CD9 immunoprecipated with the VLA␤1 mAb C9, the CD9 mAb SYB-1 or gene. K562, HEL and Daudi cells were transfected with the [−237, a control antibody. The precipitated material was revealed by Western −26] fragment of the CD9 promoter and then cultured in the presence blot using a combination of biotin-labeled C9 and streptavidinof TPA. The activity of the construction was tested after 2 days of peroxidase. culture by measuring the CAT activity as described in Materials and methods.
immature B cells bind more avidly to bone marrow fibroblasts associated molecules. The precise regulation of CD9 expression may therefore be crucial for the differentiation and it has been suggested that not only expression, but also regulation of integrin activity may be important factor modulprocess. ating this activity. 62 A molecule like CD9 may participate in this process. Indeed, mAbs to CD9 have recently been shown to increase the adhesion of pre-B cells to bone marrow fibroAcknowledgements blasts by a mechanism which involves the interaction of both VLA-4 and VLA-5 to cellular fibronectin. 16 Because the CD9 We are grateful to Dr Bréard, Dr Zardi and Dr Gulino for the generous gift of antibodies. We also thank Dr M Castagna and antigen is upregulated at an early time during TPA treatment of K562 cells, before the induction of other megakaryocytic Dr RC Carroll for useful suggestions and critical review of the manuscript. This work was supported by the association Noumarkers, and then becomes associated with VLA integrins, one may speculate that it plays a role in megakaryocytic differvelles Recherches Biomédicales, by the Association pour la Recherche sur le Cancer, by the Association Française contre entiation by modulating the activity of such integrins or other
